ArticleAdvances in radiation oncology2026
Endobronchial High-Dose-Rate Brachytherapy for Posttransplant-Associated Bronchial Stenosis: Extended Follow-up of Pulmonary Function and Subsequent Procedures.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bronchial obstruction is a significant complication after lung transplantation. First-line treatments include a variety of bronchoscopic interventions. As an additional option, there is promise in use of endobronchial brachytherapy for treatment-refractory stenotic areas. We hypothesize that high-dose-rate (HDR) brachytherapy is an effective therapy for treatment-refractory bronchial stenosis and present our institutional data on this approach. Methods and Materials: This is a retrospective review of double lung transplant patients who underwent endobronchial HDR brachytherapy from February 2005 to July 2025 for symptomatic, treatment-refractory bronchial stenosis. HDR brachytherapy was delivered via flexible bronchoscopy and insertion of a single-lumen brachytherapy catheter. Doses used were 3 or 7 gray (Gy) prescribed to 1 cm depth. Patients were followed with bronchoscopies and pulmonary function testing. Patient, treatment, and outcome data were analyzed descriptively. Percentage predicted forced expiratory volume at 1 second and intervention frequency data were compared with 2-tailed paired Results: Eight patients were included, comprising 10 brachytherapy treatments, with a median follow-up time of 72.9 months (IQR, 44.8-85.3). Most patients received 1 course of brachytherapy (62.5%), and most treatments were done with 3 Gy in 1 fraction (Fx) (60%). The remainder of patients received 2 brachytherapy treatments (37.5%), and the remainder of treatments were done with 7 Gy in 1 Fx (40%). Median time to next bronchoscopic intervention after brachytherapy was 5.8 months (IQR, 4.3-6.6). After brachytherapy, patients required significantly fewer interventions in the 6 months posttreatment than in the 6 months pretreatment ( Conclusion: Low-dose, single-Fx endobronchial HDR brachytherapy is a safe and effective therapy option for treatment-refractory benign endobronchial stenosis after double lung transplant. Treatment with higher doses per Fx and retreatment should be used with caution as they may increase risk of acute and late toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.